Tenaya Therapeutics Files 8-K on Shareholder Votes
Ticker: TNYA · Form: 8-K · Filed: May 30, 2025 · CIK: 1858848
| Field | Detail |
|---|---|
| Company | Tenaya Therapeutics, Inc. (TNYA) |
| Form Type | 8-K |
| Filed Date | May 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Tenaya Therapeutics filed an 8-K on shareholder votes. Keep an eye on what they voted on.
AI Summary
Tenaya Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on matters submitted to a vote of security holders as of May 28, 2025. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 171 Oyster Point Boulevard, Suite 500, South San Francisco, California.
Why It Matters
This filing indicates important corporate actions or decisions that have been put before Tenaya Therapeutics' shareholders for a vote, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and does not inherently present new financial or operational risks.
Key Numbers
- 001-40656 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-3789973 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- May 28, 2025 (date) — Date of earliest event reported
- May 30, 2025 (date) — Date of report
- 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080 (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Tenaya Therapeutics' security holders?
The filing states that the 8-K is for 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 28, 2025.
What is Tenaya Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080.
In which state was Tenaya Therapeutics, Inc. incorporated?
Tenaya Therapeutics, Inc. was incorporated in Delaware.
What is the SEC file number for Tenaya Therapeutics, Inc.?
The SEC file number for Tenaya Therapeutics, Inc. is 001-40656.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding Tenaya Therapeutics, Inc. (TNYA).